GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AstraZeneca PLC (NAS:AZN) » Definitions » EV-to-FCF

AstraZeneca (AstraZeneca) EV-to-FCF : 36.73 (As of Apr. 25, 2024)


View and export this data going back to 1993. Start your Free Trial

What is AstraZeneca EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, AstraZeneca's Enterprise Value is $241,184 Mil. AstraZeneca's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $6,567 Mil. Therefore, AstraZeneca's EV-to-FCF for today is 36.73.

The historical rank and industry rank for AstraZeneca's EV-to-FCF or its related term are showing as below:

AZN' s EV-to-FCF Range Over the Past 10 Years
Min: -1238.61   Med: 46.01   Max: 267.74
Current: 36.74

During the past 13 years, the highest EV-to-FCF of AstraZeneca was 267.74. The lowest was -1238.61. And the median was 46.01.

AZN's EV-to-FCF is ranked worse than
64.44% of 509 companies
in the Drug Manufacturers industry
Industry Median: 21.93 vs AZN: 36.74

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-25), AstraZeneca's stock price is $75.24. AstraZeneca's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $1.915. Therefore, AstraZeneca's PE Ratio for today is 39.29.


AstraZeneca EV-to-FCF Historical Data

The historical data trend for AstraZeneca's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AstraZeneca EV-to-FCF Chart

AstraZeneca Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 283.49 64.58 54.00 32.44 35.14

AstraZeneca Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 32.44 38.46 35.44 33.70 35.14

Competitive Comparison of AstraZeneca's EV-to-FCF

For the Drug Manufacturers - General subindustry, AstraZeneca's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AstraZeneca's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AstraZeneca's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where AstraZeneca's EV-to-FCF falls into.



AstraZeneca EV-to-FCF Calculation

AstraZeneca's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=241184.147/6567
=36.73

AstraZeneca's current Enterprise Value is $241,184 Mil.
AstraZeneca's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $6,567 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AstraZeneca  (NAS:AZN) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

AstraZeneca's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=75.24/1.915
=39.29

AstraZeneca's share price for today is $75.24.
AstraZeneca's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.915.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


AstraZeneca EV-to-FCF Related Terms

Thank you for viewing the detailed overview of AstraZeneca's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


AstraZeneca (AstraZeneca) Business Description

Address
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its revenue.

AstraZeneca (AstraZeneca) Headlines

From GuruFocus

AstraZeneca: Growth Is Still a Better Choice

By Nathan Aisenstadt 11-15-2023